PAR-25-072: Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 17, 2025.
From the official notice on Grants.gov, last changed March 31, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsRequired
- Funded byNCI
- Median yearly award$649,366
- Typical project length2 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under PAR-25-072 were run by National Cancer Institute (NCI, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-072 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-22-256 | November 23, 2022 | Closed November 17, 2024 | Closed |
Key dates
| Posted | November 18, 2024 |
|---|---|
| Deadline | November 17, 2025 |
| Archived by Grants.gov | December 23, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Is this a realistic fit?
- Most of the program's money (64% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions to improve health access for all and reflect a variety of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Funded under PAR-25-072 so far
NIH funded 5 projects under PAR-25-072 in fiscal 2026, at 5 institutions. The median yearly award was $649,366.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Bundled Outreach of Multiple Cancer Screenings for Under-screened Populations (BUNDLE) | Oregon Health & Science University | 2026 | $596,996 |
| Dissemination and Implementation of a Network-Based Facilitation Strategy to Improve Quality and Comprehensiveness of Cancer Care for Rural Patients | University of Iowa | 2026 | $668,189 |
| Evaluation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: The SHIELD (Smart Health Integration for Early Life-saving Detection) | Mayo Clinic Rochester | 2026 | $569,282 |
| Designing and Evaluating Multi-level Implementation Strategies to Address Alcohol Use within Oncology Care | University of Pennsylvania | 2026 | $649,366 |
| The Non Invasive Post Polypoectomy Surveillance Study (NIPPSS) | New York University School of Medicine | 2026 | $671,426 |
Who has won Cancer Control grants before
From fiscal 2021 to 2025, Cancer Control (93.399) awarded $814 million across 113 grant awards, an average of $7.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ecog-Acrin Medical Research Foundation, Inc. | Pennsylvania | 1 | $87.9 million |
| NRG Oncology Foundation Inc | Pennsylvania | 1 | $54.3 million |
| Alliance NCTN Foundation | Illinois | 1 | $50.2 million |
| Oregon Health & Science University | Oregon | 2 | $34.4 million |
| University of Rochester | New York | 1 | $29.8 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-072 still open?
No. It closed on November 17, 2025.
Who can apply for Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)?
Closed November 17, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-25-072?
NIH RePORTER lists 5 projects funded under PAR-25-072 in fiscal 2026, at 5 institutions. The most were at Oregon Health & Science University, University of Iowa, Mayo Clinic Rochester.
Who has won Cancer Control grants before?
The largest recipients over five fiscal years were Ecog-Acrin Medical Research Foundation, Inc., NRG Oncology Foundation Inc, Alliance NCTN Foundation. The program made 113 awards worth $814 million in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)